NATCO PHARMA
Back to Balance Sheet
|
NATCO PHARMA Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹944 Cr | ₹973 Cr | ₹683 Cr | ₹710 Cr | ₹526 Cr |
What is the latest Total Current Liabilities ratio of NATCO PHARMA ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹944 Cr |
| Mar2024 | ₹973 Cr |
| Mar2023 | ₹683 Cr |
| Mar2022 | ₹710 Cr |
| Mar2021 | ₹526 Cr |
How is Total Current Liabilities of NATCO PHARMA Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹944 Cr | -3.01 | |
| Mar2024 | ₹973 Cr | 42.41 | |
| Mar2023 | ₹683 Cr | -3.84 | |
| Mar2022 | ₹710 Cr | 35.16 | |
| Mar2021 | ₹526 Cr | - | |
Compare Total Current Liabilities of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹18,210.0 Cr | -13.1% | -7.1% | 33.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹432,096.0 Cr | -2.4% | 3% | 9.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹176,807.0 Cr | -3.3% | 3.5% | 4.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹148,718.0 Cr | -2% | 5% | 43.1% | Stock Analytics | |
| CIPLA | ₹112,971.0 Cr | -0% | 6.9% | -4.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹108,752.0 Cr | -0.3% | -3.8% | 7.3% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | -13.1% |
-7.1% |
33.6% |
| SENSEX | -0.5% |
-3.3% |
-7.6% |
You may also like the below Video Courses